Resources
JUMP TO>>
Papers | Posters
Collaboration Posters
Awarded Grants
ViQi’s AVIA™ platform, initially developed as a viral infectivity assay, uses AI-based image analysis to automate the creation of quantitative cell-based assays. This technology enables rapid assay development for any cellular phenotype, even in live, unstained cells imaged via brightfield microscopy. Read more.
Cultured cells have long been used to study cellular response to drug treatments as surrogates to how cells would respond in living organisms. Traditionally, 2D cell cultures have been used for these assays, but 3D cultures (e.g., organoids) are rapidly growing as a better analog to the cellular environment in our own bodies. Read more.
After successfully proving that AI can work on Plaque Assays as part of the initial special Covid-19 grant, phase I. ViQi now received the Phase II grant for 1 million dollars. Development of viral vaccines and antiviral drugs requires viral infectivity assays, however, the incubation periods of plaque and TCID50 assays can be as long as 14 days…. Read More.
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to accelerate the development of vaccines and anti-virals with artificial intelligence (AI) techniques. This project will develop technology to detect changes in virus-infected cells days or weeks before they can be detected manually. Read more.
In Phase I of the project, a scalable, web-based viewer and query system for large scientific images and tabular data was developed. In Phase II, novel query and analysis mechanisms are added to extract insights from large, diverse collections of scientific datasets. Read more.
Researchers are entering a new era in scientific discovery enabled by Big Data and E-Science. A growing, but largely untapped resource, is large-scale image analytics. To-date, images were only viewed, but advanced analytics now allow scientists to extract quantitative data from images. Read more.
